BOILLHEALTHCARE (01246) announced its mid-year performance for the 2025 fiscal year. The company's owners' share of the loss amounted to HK$26.972 million, which represents an increase of approximately 2.38 times compared to the same period last year.

Boill Healthcare (01246) announced its interim performance for the six months ending September 30, 2024, with revenue of approximately HK$32.53 million, a decrease of 88.16% year-on-year. The company's attributable loss was HK$26.972 million, an increase of approximately 2.38 times year-on-year, with a loss per share of 1.99 HK cents. The announcement stated that the decrease in revenue was mainly due to a decrease in the net impact of properties delivered under the Yangzhong project. The increase in net loss was mainly due to an increase in borrowing leading to increased financial costs, expected credit losses on financial guarantee contracts, and a decrease in gross profit, partially offset by a decrease in administrative and other expenses.